MedTrace Logo

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.

NCT03697226 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2021-01-13

No results posted yet for this study

Summary

This study evaluates the use of ABI-1968, a topical cream, in the treatment of cervical precancerous lesions in females without human immunodeficiency virus (HIV) infection.

Conditions

  • HSIL of Cervix
  • HSIL, High Grade Squamous Intraepithelial Lesions
  • High-Grade Cervical Intraepithelial Neoplasia
  • Human Papilloma Virus
  • HIV Negative
  • Cervical Cancer
  • CIN - Cervical Intraepithelial Neoplasia
  • Cervical Neoplasm
  • Cervical Dysplasia

Interventions

DRUG

Topical ABI-1968

Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts

Sponsors & Collaborators

  • Antiva Biosciences

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-21
Primary Completion
2020-05-26
Completion
2020-06-12
FDA Drug
Yes

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03697226 on ClinicalTrials.gov